Cipla
- Market Cap
- ₹1,14,312 Cr
- P/E
- 39.45
Key Fundamentals
MidcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 15.50%
- Debt to Equity
- 0.02
- EPS (TTM)
- ₹35.87
- Book Value
- ₹438.15
- Market Cap
- ₹1,14,312 Cr
- P/E (TTM)
- 39.45
- P/B
- 3.23
- ROE
- 11.60%
- Dividend Yield
- 0.92%
- EBITDA
- ₹6,765 Cr
- 52W High
- ₹1,539.70
- 52W Low
- ₹1,165.70
- Day Range
- ₹1,401.20 – ₹1,428.00
- Volume
- 14,84,426
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| Median 7 companies | 1,884.90 | 41.44 | 1,23,980 | 5.07 | 0.57% | 16.50% | 17.80% | 28,139 | 2,855 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 44
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 68
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 5
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 80
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 21
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 51
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 25.7%
Weaknesses
2- The company has delivered a poor sales growth of 8.01% over past five years.
- Promoter holding has decreased over last 3 years: -4.26%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 0 | 7 | 12 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 60.85
- Neutral
- MACD (12,26,9)
- 13.97
- Bullish
- SMA (50)
- 1,367.69
- Bullish
- SMA (200)
- 1,365.90
- Bullish
As of
Analyst Rating
22 of 35 analysts rate Buy, 12 Hold, 1 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +7.40% |
|---|---|
| 5Y | +8.01% |
| 3Y | +7.37% |
| 1Y | +2.23% |
| TTM | −0.74% |
Net profit
| 10Y | +10.82% |
|---|---|
| 5Y | +10.08% |
| 3Y | +10.88% |
| 1Y | −26.70% |
| TTM | −47.46% |
Operating cash flow
| 10Y | +8.51% |
|---|---|
| 5Y | +0.97% |
| 3Y | +6.76% |
| 1Y | −21.28% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +2.91 pp |
|---|---|
| 5Y | −1.30 pp |
| 3Y | −1.20 pp |
| 1Y | −4.98 pp |
| TTM | −8.38 pp |
Revenue by year
| Mar 2017 | ₹14,394 Cr |
|---|---|
| Mar 2018 | ₹15,156 Cr |
| Mar 2019 | ₹16,362 Cr |
| Mar 2020 | ₹17,132 Cr |
| Mar 2021 | ₹19,160 Cr |
| Mar 2022 | ₹21,763 Cr |
| Mar 2023 | ₹22,753 Cr |
| Mar 2024 | ₹25,774 Cr |
| Mar 2025 | ₹27,548 Cr |
| Mar 2026 | ₹28,163 Cr |
Net profit by year
| Mar 2017 | ₹1,035 Cr |
|---|---|
| Mar 2018 | ₹1,417 Cr |
| Mar 2019 | ₹1,492 Cr |
| Mar 2020 | ₹1,500 Cr |
| Mar 2021 | ₹2,389 Cr |
| Mar 2022 | ₹2,547 Cr |
| Mar 2023 | ₹2,833 Cr |
| Mar 2024 | ₹4,154 Cr |
| Mar 2025 | ₹5,269 Cr |
| Mar 2026 | ₹3,862 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Cipla Ltd trades at ₹1,394.5 as of 2026-11-16 with a market cap of ₹1,12,655.86 crore and a P/E (TTM) of 38.88. The company is virtually debt-free with a debt-to-equity ratio of 0.02, but TTM profit has contracted sharply at -43% while sales growth turned negative at -1% TTM, marking a notable departure from its longer-term compounding trajectory.
- Cipla is almost debt-free with a debt-to-equity ratio of just 0.02, giving it significant financial flexibility and resilience against interest rate cycles.
- The company has compounded profits at 11% over 10 years and 10% over both 3-year and 5-year periods, reflecting a consistent long-term earnings track record.
- Return on equity has averaged 13% over the past 10 years and 15% over 3 years, indicating sustained capital efficiency above many pharmaceutical peers.
- ROCE stands at 14.88% as of 2026-11-16, supported by the near-zero leverage on the balance sheet, suggesting strong operating returns on total capital employed.
- The company maintains a healthy dividend payout ratio of 25.7%, with a current dividend yield of 0.93%, providing a degree of income return to shareholders.
- Revenue has compounded at 7-8% over 3, 5, and 10-year horizons, demonstrating steady top-line expansion over multiple market cycles.
- The stock trades 9.4% below its 52-week high of ₹1,539.7, while remaining 19.6% above its 52-week low of ₹1,165.7, suggesting it has found support well above recent trough levels.
- TTM profit growth has turned sharply negative at -43%, a dramatic reversal from the 10% compounded profit growth seen over 3 and 5 years, raising questions about near-term earnings durability.
- TTM sales growth has turned negative at -1%, breaking the 7-8% compounding trend seen over longer periods and signalling potential demand or pricing headwinds.
- At a P/E (TTM) of 38.88, the valuation appears stretched relative to the current earnings contraction, with profits declining 43% on a trailing basis.
- Promoter holding has decreased by 4.26% over the last 3 years, which may signal reduced promoter confidence or dilution-related concerns.
- The 1-year stock CAGR is -9%, underperforming the broader market and reflecting investor unease about the recent earnings trajectory.
- Last year's ROE of 12% has dipped below the 3-year average of 15% and the 5-year average of 14%, indicating a declining trend in return on shareholder equity.
- Price-to-book ratio of 3.18 combined with a falling ROE of 11.21% suggests the market is paying a premium for returns that are currently compressing.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Cipla's US operations got a clean bill of health with NAI status for its InvaGen facility, reinforcing its regulatory standing in a key market. The DRI searches related to drug import classification are a near-term overhang worth monitoring, though details remain limited. Leadership strengthening via a new Global CTOS and board appointment signals focus on operational scale. The regulatory trajectory is positive on the US front, but the DRI matter introduces some uncertainty domestically.
- DRI searches Mumbai office, depot Nov 17
The Directorate of Revenue Intelligence searched Cipla's Mumbai office and Bhivandi depot over classification of imported drugs. Two locations were covered in the operation.
- US facility gets USFDA NAI status Nov 18
Cipla's InvaGen facility in the US received USFDA NAI (No Action Indicated) status, the most favourable inspection outcome, indicating no objectionable conditions were found.
- New Global CTOS appointed Nov 4
Cipla appointed Vikram Janakiraman as Global Chief Technical Operating Officer effective December 7, 2026. He brings 30 years of experience from BCG.
- Rashmi Joshi named Independent Director Oct 27
Cipla appointed Rashmi Joshi as independent director for a five-year term effective October 27, 2026. Shareholder e-voting runs November 17 to December 16, 2026.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,678 | 6,604 | 6,163 | 6,694 | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 | 7,404 |
| Expenses | 4,944 | 4,856 | 4,847 | 4,978 | 5,165 | 5,084 | 5,192 | 5,179 | 5,695 | 5,819 | 5,586 | 5,927 | 6,016 |
| Operating Profit | 1,734 | 1,748 | 1,316 | 1,716 | 1,886 | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 | 955 | 1,192 | 1,388 |
| OPM % | 26% | 26% | 21% | 26% | 27% | 28% | 23% | 26% | 25% | 18% | 15% | 17% | 19% |
| Other Income | 176 | 185 | 249 | 160 | 191 | 222 | 289 | 259 | 269 | 206 | 148 | 211 | 151 |
| Interest | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 | 14 | 13 | 17 | 17 |
| Depreciation | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 | 278 | 383 | 304 | 345 |
| Exceptional Items | — | −195 | — | — | — | — | — | — | — | −276 | — | — | — |
| PBT | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 | 1,177 |
| Tax % | 28% | 28% | 26% | 27% | 27% | 17% | 19% | 27% | 27% | 24% | 22% | 27% | 27% |
| Net Profit | 1,155 | 1,068 | 932 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 | 852 |
| EPS (₹) | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 | 15.13 | 16.06 | 16.73 | 8.37 | 6.87 | 9.77 | 10.86 |
| YoY Sales growth | 15 | 14 | 7 | 6 | 6 | 7 | 9 | 4 | 8 | 0 | −3 | 2 | −2 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,345 | 13,790 | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 | 28,139 |
| Expenses | 9,183 | 11,310 | 11,898 | 12,329 | 13,265 | 13,926 | 14,907 | 17,211 | 17,726 | 19,483 | 20,420 | 22,280 | 23,349 |
| Operating Profit | 2,163 | 2,480 | 2,496 | 2,826 | 3,097 | 3,206 | 4,252 | 4,553 | 5,027 | 6,291 | 7,128 | 5,883 | 4,790 |
| OPM % | 19% | 18% | 17% | 19% | 19% | 19% | 22% | 21% | 22% | 24% | 26% | 21% | 17% |
| Other Income | 164 | 208 | 208 | 358 | 477 | 344 | 266 | 281 | 475 | 747 | 862 | 882 | 441 |
| Interest | 168 | 207 | 159 | 114 | 168 | 197 | 161 | 106 | 110 | 90 | 62 | 54 | 61 |
| Depreciation | 505 | 754 | 1,323 | 1,323 | 1,326 | 1,175 | 1,068 | 1,052 | 1,172 | 1,051 | 1,107 | 1,211 | 1,310 |
| Exceptional Items | — | — | — | −77.52 | — | — | — | −182 | −182 | −195 | — | −276 | — |
| PBT | 1,654 | 1,727 | 1,222 | 1,669 | 2,079 | 2,178 | 3,290 | 3,493 | 4,038 | 5,702 | 6,821 | 5,224 | 3,859 |
| Tax % | 24% | 19% | 15% | 15% | 27% | 29% | 27% | 27% | 30% | 27% | 22% | 26% | — |
| Net Profit | 1,229 | 1,383 | 1,035 | 1,417 | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 | 2,854 |
| EPS (₹) | 14.71 | 16.93 | 12.51 | 17.52 | 18.96 | 19.18 | 29.82 | 31.19 | 34.71 | 51.05 | 65.28 | 48.02 | 35.87 |
| Div. Payout % | 14% | 12% | 16% | 17% | 16% | 21% | 17% | 16% | 24% | 25% | 25% | 27% | — |
| Sales growth | 12 | 22 | 4 | 5 | 8 | 5 | 12 | 14 | 5 | 13 | 7 | 2 | −1 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 | 162 | 162 |
| Reserves | 10,641 | 11,356 | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 | 26,545 | 31,032 | 34,270 | 35,234 |
| Borrowings | 1,703 | 5,202 | 4,113 | 4,098 | 4,316 | 2,816 | 2,014 | 1,056 | 803 | 559 | 438 | 614 | 699 |
| Other Liabilities | 3,166 | 4,331 | 4,213 | 4,346 | 4,433 | 4,843 | 4,514 | 4,960 | 5,089 | 5,267 | 5,702 | 7,297 | 7,339 |
| Total Liabilities | 15,670 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,300 | 32,533 | 37,334 | 42,343 | 43,434 |
| Fixed Assets | 6,830 | 9,368 | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,160 | 9,607 | 10,006 | 12,434 | 13,661 |
| CWIP | 581 | 2,061 | 1,683 | 981 | 676 | 825 | 969 | 766 | 1,093 | 1,153 | 1,566 | 2,042 | 1,711 |
| Investments | 640 | 759 | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 | 7,933 | 8,223 | 6,686 |
| Other Assets | 7,620 | 8,862 | 8,721 | 10,483 | 10,923 | 11,444 | 11,661 | 13,857 | 15,384 | 16,323 | 17,828 | 19,643 | 21,376 |
| Total Assets | 15,670 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,300 | 32,533 | 37,334 | 42,343 | 43,434 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | 4,134 | 5,005 | 3,940 |
| Investing | −950 | −4,533 | −1,304 | −834 | −1,688 | 114 | −2,374 | −1,858 | −2,376 | −2,982 | −3,682 | −2,234 |
| Financing | 165 | 3,104 | −1,326 | −385 | −349 | −2,949 | −1,240 | −1,600 | −958 | −1,200 | −1,293 | −1,234 |
| Net Cash Flow | 388 | 312 | −248 | 243 | −345 | 234 | 141 | −132 | −97 | −49 | 30 | 473 |
| Free Cash Flow | 548 | 688 | 1,284 | 723 | 1,187 | 2,083 | 2,964 | 2,645 | 2,102 | 2,819 | 3,490 | 928 |
| CFO/EBITDA | 72 | 91 | 113 | 77 | 74 | 122 | 113 | 98 | 90 | 91 | 94 | 94 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 62 | 65 | 75 | 93 | 83 | 66 | 57 | 65 | 68 | 73 | 73 |
| Inventory Days | 329 | 273 | 239 | 271 | 250 | 267 | 232 | 230 | 228 | 217 | 231 | 252 |
| Days Payable | 126 | 106 | 108 | 142 | 123 | 139 | 103 | 108 | 112 | 102 | 116 | 123 |
| Cash Conversion Cycle | 267 | 230 | 196 | 204 | 220 | 211 | 195 | 180 | 181 | 182 | 188 | 202 |
| Working Capital Days | 89 | −10 | 99 | 118 | 132 | 113 | 94 | 95 | 113 | 120 | 128 | 106 |
| ROCE % | 15% | 13% | 7% | 9% | 11% | 12% | 17% | 17% | 18% | 23% | 23% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Cipla insights
73 extracted metrics across FY11–FY27.
Documents
- Q2 FY27 concall · Oct 2026Transcript PPT Recording
- Q1 FY27 concall · Jul 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Jan 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- 10 Sep 2026
- 19 Dec 2025
- 26 Aug 2025
- 20 Dec 2024
- 8 Oct 2024
- General announcements 17 Nov 2026
- General announcements 16 Nov 2026
Frequently Asked Questions about Cipla
What does Cipla Ltd do?
Where is Cipla Ltd (CIPLA) listed?
Which sector does Cipla Ltd belong to?
What is the market capitalisation of Cipla Ltd?
What is the PE ratio of Cipla Ltd?
What is the 52-week high and low of Cipla Ltd?
Does Cipla Ltd pay dividends?
What is the Return on Equity (ROE) of Cipla Ltd?
Company Information
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CIPLA.md for Cipla Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.